Navigation Links
Roche Files IND for Second Genmab Antibody
Date:12/20/2007

Summary: Genmab's Partner Roche has Filed an IND With the US FDA for a

Genmab Antibody

COPENHAGEN, August 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that its partner Roche has filed an Investigational New Drug application (IND) with the US Food and Drug Administration for a Genmab antibody developed under the companies' collaboration. Genmab will receive a milestone payment from Roche which does not influence Genmab's financial guidance for 2007.

Under the agreement with Roche, Genmab utilizes its broad antibody expertise and development capabilities to create human antibodies to a broad range of disease targets identified by Roche. Genmab receives milestone and royalty payments based on successful products. In certain circumstances, Genmab may obtain rights to develop products based on disease targets identified by Roche. If all goals are reached, the value of the collaboration to Genmab could be USD 100 million, plus royalties.

"This will be the second antibody produced under our collaboration with Roche to enter the clinic and Genmab's seventh antibody to enter clinical development overall," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "Our partnership with Roche continues to bear fruit and add value to Genmab's expanding product pipeline."

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders.

As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's prod
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Roche Extends Tender Offer for Ventana
3. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitors
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. Med Ad News Honors Roche as Company of the Year
8. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
11. Kosan to Reacquire Epothilone Program From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Physicians ... its cardiovascular pharmacogenetics menu, which enables healthcare providers ... With PCLS’s evidence-based results, healthcare providers are ... optimize their therapy, while minimizing risks for adverse ... U.S., according to the FDA [1] more than ...
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... the University of Illinois helped lead a collaborative ... for serious Staphylococcus aureus (Staph) infections. The research, ... of Science magazine, comes at a time when ... methicillin-resistant S. aureus) are spreading in epidemic proportions ...
... Pipeline ... Continues to Mature, SOUTH SAN FRANCISCO, Calif., Feb. 14 ... full,year and fourth quarter ended December 31, 2007., Revenues for the ... revenues for the full year was primarily due to,revenue recognition associated with ...
... IRVINE, Calif., Feb. 14 SectorWatch.biz announces the,availability ... the news and,driving markets today., Investors can ... by,visiting: http://www.SectorWatch.biz -- Click on MarketStats, ... include:,CardioVascular Bio Therapeutics, Inc. (OTC Bulletin Board: CVBT), ...
Cached Biology Technology:New approach may render disease-causing staph harmless 2New approach may render disease-causing staph harmless 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA 2
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
(Date:10/17/2014)... the University of Copenhagen have shown for the first ... of Cystic fibrosis patients, giving them the opportunity to ... chronic infections. , The study also discovered the bacterial ... patients was halted or slowed down by the immune ... the oxygen and helped "suffocate" the bacteria, forcing the ...
(Date:10/16/2014)... Researchers at William and Mary,s Virginia Institute of ... from the Environmental Protection Agency to identify the ... and to develop tools to help local governments ... project depends critically on a dataset of tidal-marsh ... 1970s. Only with this historical baseline can today,s ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3
... with research associate Jerilyn Walker and assistant professor Miriam Konkel, ... ancient jumping genes called Alu, which are more than 16 ... the Zoological Society of San Diego and the Institute of ... open access journal Mobile DNA . These tiny ...
... are being investigated as a way of improving drug response ... launched today (Monday). Scientists at the Cancer Research UK ... (ECMC) in Leicester will investigate whether tablets containing curcumin ... to the standard treatment for bowel cancer that has spread. ...
... is available in German . Halle/Saale. In ... special strategies. These differ in part considerably from the propagation ... Dr. Sonja Knapp of the Helmholtz Centre for Environmental Research ... current issue of the scientific journal Ecology Letters . ...
Cached Biology News:LSU research finds orangutans host ancient jumping genes 2Trial launched into curry chemical's cancer-fighting properties 2Different recipes for success in the world of plants 2Different recipes for success in the world of plants 3
MOUSE ANTI HUMAN NPM...
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
Antibodies were affinity purified using epitopes specific to JLP immobilized on solid support....
... et.al. (1997) • Contains short ... biochemistry & molecular biology, arranged ... Entries give details of biochemical ... which they are involved and ...
Biology Products: